[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201790717A1 - Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека - Google Patents

Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека

Info

Publication number
EA201790717A1
EA201790717A1 EA201790717A EA201790717A EA201790717A1 EA 201790717 A1 EA201790717 A1 EA 201790717A1 EA 201790717 A EA201790717 A EA 201790717A EA 201790717 A EA201790717 A EA 201790717A EA 201790717 A1 EA201790717 A1 EA 201790717A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunity against
protective immunity
compositions
methods
immunodeficiency virus
Prior art date
Application number
EA201790717A
Other languages
English (en)
Other versions
EA037583B1 (ru
Inventor
Дэн Бараух
Йоханна Схейтемакер
Мария Грация Пау
Манен Даниелль Ван
Фрэнк Томака
Дженнифер Анн Хендрикс
Original Assignee
Бет Изрейэл Диконисс Медикал Сентер, Инк.
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бет Изрейэл Диконисс Медикал Сентер, Инк., Янссен Вэксинс Энд Превеншн Б.В. filed Critical Бет Изрейэл Диконисс Медикал Сентер, Инк.
Publication of EA201790717A1 publication Critical patent/EA201790717A1/ru
Publication of EA037583B1 publication Critical patent/EA037583B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Описаны композиции, вакцины и способы индукции защитного иммунитета против вируса иммунодефицита человека (ВИЧ). Гетерологичные комбинированные вакцины, состоящие из одного или более вирусных экспрессирующих векторов и выделенного антигенного полипептида, индуцировали сильный защитный иммунитет против инфекций ВИЧ одного или множества субтипов.
EA201790717A 2014-09-26 2015-09-24 Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека EA037583B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056059P 2014-09-26 2014-09-26
PCT/US2015/051891 WO2016049287A1 (en) 2014-09-26 2015-09-24 Methods and compositions for inducing protective immunity against human immunodeficiency virus infection

Publications (2)

Publication Number Publication Date
EA201790717A1 true EA201790717A1 (ru) 2018-02-28
EA037583B1 EA037583B1 (ru) 2021-04-16

Family

ID=55581992

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790717A EA037583B1 (ru) 2014-09-26 2015-09-24 Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
EA202092521A EA202092521A1 (ru) 2014-09-26 2015-09-24 Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202092521A EA202092521A1 (ru) 2014-09-26 2015-09-24 Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека

Country Status (28)

Country Link
US (4) US10137191B2 (ru)
EP (2) EP3868398A1 (ru)
JP (2) JP6438575B2 (ru)
KR (2) KR102159626B1 (ru)
CN (2) CN106999571B (ru)
AP (1) AP2017009846A0 (ru)
AU (2) AU2015320574B2 (ru)
BR (1) BR112017005917A2 (ru)
CA (1) CA2961024A1 (ru)
CY (1) CY1124254T1 (ru)
DK (1) DK3197489T3 (ru)
EA (2) EA037583B1 (ru)
ES (1) ES2865150T3 (ru)
HR (1) HRP20210608T1 (ru)
HU (1) HUE053585T2 (ru)
IL (2) IL251114B (ru)
LT (1) LT3197489T (ru)
MA (1) MA40765B1 (ru)
MX (2) MX2017003946A (ru)
MY (1) MY175620A (ru)
PH (1) PH12017500449A1 (ru)
PL (1) PL3197489T3 (ru)
PT (1) PT3197489T (ru)
RS (1) RS61902B1 (ru)
SG (1) SG11201702110RA (ru)
SI (1) SI3197489T1 (ru)
WO (1) WO2016049287A1 (ru)
ZA (1) ZA201702053B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175620A (en) * 2014-09-26 2020-07-02 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
BR112018011122A2 (pt) 2015-12-15 2018-11-21 Janssen Vaccines & Prevention B.V. antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
CA3014419A1 (en) 2016-02-16 2017-08-24 Geovax Inc. Multivalent hiv vaccine boost compositions and methods of use
JP6595132B2 (ja) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖワクチン製剤
CN110494159A (zh) * 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
HUE052008T2 (hu) 2016-09-15 2021-04-28 Janssen Vaccines & Prevention Bv Trimert stabilizáló HIV-burokfehérje-mutációk
EA202090049A1 (ru) * 2017-06-15 2020-04-15 Янссен Вэксинс Энд Превеншн Б.В. Поксвирусные векторы, кодирующие антигены вич, и способы их применения
BR112020000867A2 (pt) 2017-07-19 2020-07-21 Janssen Vaccines & Prevention B.V. mutações da proteína do envelope do hiv estabilizando o trímero
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
WO2019055888A1 (en) * 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
US11517618B2 (en) * 2018-09-25 2022-12-06 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
US20220211835A1 (en) * 2019-04-17 2022-07-07 The Wistar Institute Replication Deficient Adenoviral Vectors for HIV Vaccine Applications
WO2020237052A1 (en) * 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
CA3141454A1 (en) * 2019-05-22 2020-11-26 Aelix Therapeutics, S.L. Dosage regimens for vaccines
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン並びにその作製方法及び使用方法
AU2020381082B2 (en) * 2019-11-07 2022-09-22 Janssen Vaccines & Prevention B.V. Protein purification
PE20241071A1 (es) 2021-01-14 2024-05-13 Gilead Sciences Inc Vacunas contra el vih y metodos de uso
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
DK1054064T4 (da) 1999-05-17 2010-05-03 Crucell Holland Bv Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
CZ295808B6 (cs) 2000-11-23 2005-11-16 Bavarian Nordic A/S Modifikovaný virus vakcinie typu Ankara
CA2452119C (en) 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
CA2466413C (en) 2001-12-04 2014-11-04 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
EP1497440B1 (en) 2002-04-25 2008-08-20 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
CA2505583C (en) 2002-12-03 2014-07-15 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
CA2520637A1 (en) 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
WO2005027840A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
CN107723298A (zh) 2004-01-23 2018-02-23 Msd意大利有限公司 黑猩猩腺病毒疫苗载运体
WO2006002079A2 (en) 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
JP4772045B2 (ja) 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
US9453239B2 (en) 2004-08-27 2016-09-27 Emory University Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
MX2007004188A (es) 2004-10-13 2007-10-11 Crucell Holland Bv Vectores adenovirales mejorados y usos de los mismos.
WO2006050394A2 (en) * 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
CA2656741A1 (en) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
WO2007024941A2 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20110076298A1 (en) 2006-06-19 2011-03-31 Olson William C Soluble stabilized trimeric hiv env proteins and uses thereof
WO2008063331A2 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
SI2137210T1 (sl) 2007-03-02 2017-01-31 Glaxosmithkline Biologicals S.A. Nov postopek in sestavki
HUE037270T2 (hu) * 2008-10-10 2018-08-28 Childrens Medical Center Biokémiailag stabilizált HIV-1 ENV trimer vakcina
NZ602504A (en) 2008-11-18 2014-01-31 Beth Israel Hospital Antiviral vaccines with improved cellular immunogenicity
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
SI2391638T1 (sl) 2009-02-02 2018-10-30 Glaxosmithkline Biologicals Sa Nukleinskokislinske in aminokislinske sekvence opičjega adenovirusa, vektorji, ki le-te vsebujejo, in njihova uporaba
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
CN102711794B (zh) 2010-01-04 2015-11-25 Kj生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
CA2786333C (en) 2010-01-28 2018-03-20 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of mva
CA2786835C (en) * 2010-02-15 2021-08-31 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
SI3556396T1 (sl) 2010-08-31 2022-09-30 Theraclone Sciences, Inc. Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV)
AU2011316164B2 (en) 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
AU2011343798B2 (en) * 2010-12-14 2016-07-14 Janssen Vaccines & Prevention B.V. Adenovirus serotype 26 and serotype 35 filovirus vaccines
US20140348791A1 (en) 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
US9683268B2 (en) 2012-09-19 2017-06-20 Beth Israel Deaconess Viruses associated with immunodeficiency and enteropathy and methods using same
CN105051198A (zh) 2012-11-16 2015-11-11 貝丝以色列女执事医疗中心 重组腺病毒及其用途
JP6357487B2 (ja) 2013-01-07 2018-07-11 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 安定化ヒト免疫不全ウイルス（ｈｉｖ）エンベロープ（ｅｎｖ）トリマーワクチン及びそれを使用する方法
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CN103992396B (zh) * 2014-04-17 2017-03-29 南开大学 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
MY175620A (en) 2014-09-26 2020-07-02 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
BR112018011122A2 (pt) 2015-12-15 2018-11-21 Janssen Vaccines & Prevention B.V. antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
CN110494159A (zh) * 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法

Also Published As

Publication number Publication date
SI3197489T1 (sl) 2021-08-31
CY1124254T1 (el) 2022-07-22
ES2865150T3 (es) 2021-10-15
MX2020013153A (es) 2021-02-18
BR112017005917A2 (pt) 2017-12-12
IL251114B (en) 2019-05-30
SG11201702110RA (en) 2017-04-27
US10137191B2 (en) 2018-11-27
HUE053585T2 (hu) 2021-07-28
AU2018267669B2 (en) 2020-03-05
MA40765A (fr) 2017-08-02
IL265733B (en) 2021-05-31
CN106999571A (zh) 2017-08-01
MA40765B1 (fr) 2021-04-30
US20180250385A1 (en) 2018-09-06
MX2017003946A (es) 2017-12-20
CA2961024A1 (en) 2016-03-31
US20160089432A1 (en) 2016-03-31
CN112121160A (zh) 2020-12-25
NZ730841A (en) 2021-08-27
IL251114A0 (en) 2017-04-30
EP3197489A1 (en) 2017-08-02
WO2016049287A1 (en) 2016-03-31
KR20170066454A (ko) 2017-06-14
EA202092521A1 (ru) 2021-05-31
US10471137B2 (en) 2019-11-12
PL3197489T3 (pl) 2021-11-08
AP2017009846A0 (en) 2017-03-31
US20200030437A1 (en) 2020-01-30
HRP20210608T1 (hr) 2021-06-11
AU2015320574A1 (en) 2017-04-06
EA037583B1 (ru) 2021-04-16
EP3197489B1 (en) 2021-02-17
KR102159626B1 (ko) 2020-09-25
US11207400B2 (en) 2021-12-28
IL265733A (en) 2019-05-30
AU2015320574B2 (en) 2018-12-06
JP6625716B2 (ja) 2019-12-25
MY175620A (en) 2020-07-02
ZA201702053B (en) 2021-09-29
RS61902B1 (sr) 2021-06-30
EP3197489A4 (en) 2018-03-14
US20220096622A1 (en) 2022-03-31
CN106999571B (zh) 2020-10-02
JP2017531627A (ja) 2017-10-26
JP6438575B2 (ja) 2018-12-12
JP2019038849A (ja) 2019-03-14
LT3197489T (lt) 2021-07-26
PT3197489T (pt) 2021-04-30
AU2018267669A1 (en) 2018-12-13
KR101971808B1 (ko) 2019-04-23
PH12017500449A1 (en) 2017-07-31
EP3868398A1 (en) 2021-08-25
DK3197489T3 (da) 2021-04-19
KR20190042736A (ko) 2019-04-24

Similar Documents

Publication Publication Date Title
EA201790717A1 (ru) Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
PH12019500854A1 (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
WO2015134368A3 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
EA201891555A1 (ru) Вирус вакцины от репродуктивно-респираторного синдрома свиней
AU2015364253B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
PL3491139T3 (pl) Wektory lentiwirusowe do ekspresji antygenów wirusa zapalenia wątroby typu B (HBV)
EA202191862A3 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
EA201992167A1 (ru) Вакцина
GB201702193D0 (en) Hepatitis E virus vaccine
TH1501003876A (th) วัคซีนของไทรเมอร์ของถุงหุ้ม (Env) ของไวรัสโรคภูมิคุ้มกันบกพร่องของ มนุษย์ซึ่งทำให้เกิดเสถียรภาพ (HIV) และวิธีการของการใช้ที่เหมือนกัน